Table 3.
Evaluation of pre- and post-Hajj IgG antibody for MERS-CoV using rS1 Enzyme-Linked Immunosorbent Assay (ELISA).
| Year | Pre-Hajj N (%) (95% CI) |
Post-Hajj N (%) (95% CI) |
Seroconversion (≥ 4-fold increase in titre) N (%) | ||
|---|---|---|---|---|---|
| Seronegative (ELISA OD ratio < 0.3) | Seropositive (ELISA OD ratio ≥ 0.3) | Seronegative (ELISA OD ratio < 0.3) | Seropositive (ELISA OD ratio ≥ 0.3) | ||
| 2016 N = 318 |
311 (97.8) (0.08–0.09) |
7 (2.2) (0.32–0.41) |
306 (96.2) (0.08–0.09) |
12 (3.8) (0.33–0.55) | 1 (0.3) |
| 2017 N = 905 |
882 (97.5) (0.08–0.09) |
23 (2.5) (0.44–0.62) |
880 (97.2) (0.08–0.09) |
25 (2.8) (0.39–0.70) | 5 (0.6) |
| 2018 N = 752 |
732 (97.3) (0.06–0.07) |
20 (2.7) (0.36–0.90) |
728 (96.8) (0.06–0.07) |
24 (3.2) (0.45–0.74) | 6 (0.8) |
| Overall N (%) N = 1,975 |
1925 (97.5) | 50 (2.5) | 1914 (96.9) | 61 (3.1) | 12 (0.6) |
*95% CI pertains to the range of ELISA OD ratios among the seronegative and seropositive samples.